HERTFORDSHIRE, England and
PITTSBURGH, Aug. 25, 2015 /PRNewswire/ -- Mylan N.V.
(Nasdaq: MYL) today announced the U.S. launch of Piperacillin and
Tazobactam for Injection USP, 3.375g Single-dose Vials, which is
the generic version of Pfizer's Zosyn® Injection. This
product is a combination penicillin-class antibacterial and
beta-lactamase inhibitor indicated for the treatment of patients
with moderate to severe infections caused by susceptible isolates
of certain bacteria.
Piperacillin and Tazobactam for Injection USP, 3.375g
Single-dose Vials had U.S. sales of approximately $72.1 million for the 12 months ending
June 30, 2015, according to IMS
Health. Mylan's launch of this product adds to the company's
growing portfolio of more than 145 injectable products available to
patients in the U.S. across a broad array of therapeutic categories
including oncology, anti-infectives, anesthesia/pain management and
cardiovascular.
Currently, Mylan has 267 ANDAs pending FDA approval representing
$101.3 billion in annual brand sales,
according to IMS Health. Fifty of these pending ANDAs are potential
first-to-file opportunities, representing $33.4 billion in annual brand sales, for the 12
months ending December 31, 2014,
according to IMS Health.
Mylan is a global pharmaceutical company committed to setting
new standards in healthcare. Working together around the world to
provide 7 billion people access to high quality medicine, we
innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We offer a growing
portfolio of around 1,400 generic pharmaceuticals and several brand
medications. In addition, we offer a wide range of antiretroviral
therapies, upon which nearly 50% of HIV/AIDS patients in developing
countries depend. We also operate one of the largest active
pharmaceutical ingredient manufacturers and currently market
products in about 145 countries and territories. Our workforce of
approximately 30,000 people is dedicated to creating better health
for a better world, one person at a time. Learn more at
mylan.com.
This press release includes statements that constitute
"forward-looking statements," including with regard to the
company's strategy, future growth and performance. These statements
are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Because such statements
inherently involve risks and uncertainties, actual future results
may differ materially from those expressed or implied by such
forward-looking statements. Factors that could cause or contribute
to such differences include, but are not limited to: the impacts of
competition; changes in economic and financial conditions of the
company's business; strategies by competitors or other third
parties to delay or prevent product introductions; risks inherent
in legal and regulatory processes; uncertainties and matters beyond
the control of management; and the other risks detailed in the
company's filings with the Securities and Exchange Commission. The
company undertakes no obligation to update these statements for
revisions or changes after the date of this release.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mylan-launches-generic-zosyn-injection-300133010.html
SOURCE Mylan N.V.